Rezolute Launches Underwritten Stock and Pre-Funded Warrant Offering Days After $400M Shelf
RZLT has more than doubled off its 52-week low of $1.07.
Summary
Rezolute is raising money through a Morgan Stanley-led underwritten offering of common stock and pre-funded warrants, launched under the $400M universal shelf it put in place on November 5. The timing is telling: cash stood at $90.0M at the end of Q1 fiscal 2027, down from $107.8M, and the company is burning roughly $18.5M a quarter while it waits on upLIFT topline data due mid-December 2026. This comes just over a week after the sunRIZE trial in congenital hyperinsulinism missed its primary endpoint, so the raise lands with the stock already under pressure and the lead program's outlook clouded. Terms — size, price and discount — are not yet disclosed; the pricing of this deal is the number that matters for existing holders. upLIFT topline in mid-December is the next hard catalyst for the story.
At the time of this announcement, RZLT was trading at $4.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $374.3M. The 52-week trading range was $1.07 to $11.17. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.